Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3D Global BiotechROCO:6808 -1.42%69 3-Year ROIIC % is 22.75 as of Dec. 2025, which is 53% below its 10-year median of 47.90. GuruFocus rates ROCO:6808 with a GF Score™ of 69/100 and a GF Value™ of NT$187.50 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 1,319 Biotechnology companies, 3D Global Biotech ranks better than 65.88% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
3D Global Biotech's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 22.75%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for 3D Global Biotech's 3-Year ROIIC % or its related term are showing as below:
ROCO:6808's 3-Year ROIIC % is ranked better than 65.88% of 1319
companies
in the Biotechnology industry
Industry Median: -4.44
vs ROCO:6808: 22.75
3D Global Biotech (ROCO:6808) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
3D Global Biotech 3-Year ROIIC % Related Terms
3D Global Biotech 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for 3D Global Biotech's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6808 vs VRTX, REGN, RVMD: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, 3D Global Biotech's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3D Global Biotech 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3D Global Biotech's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where 3D Global Biotech's 3-Year ROIIC % falls into.
3D Global Biotech's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 44.219 (Dec. 2025) - -53.493609 (Dec. 2022) )
/
( 594.426 (Dec. 2025) - 164.857 (Dec. 2022) )
=
97.712609
/
429.569
=
22.75%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
3D Global Biotech (ROCO:6808) has a 3-Year ROIIC % of 22.75 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on 3D Global Biotech and its competitors. This is 53% below median its historical median of 47.90. Over the past decade, 3D Global Biotech's 3-Year ROIIC % has ranged from 22.75 to 134.47. According to the industry distribution chart, 3D Global Biotech ranks #450 out of 1319 companies in the Biotechnology industry, placing it in the top 34.1%.
Is 3D Global Biotech's 3-Year ROIIC % too high?
3D Global Biotech's current 3-Year ROIIC % of 22.75 is 53% below median its 10-year median of 47.90. Over the past 10 years, this metric has ranged from a low of 22.75 to a high of 134.47. Based on the distribution chart, 3D Global Biotech ranks #450 out of 1319 companies in the Biotechnology industry, which is above the industry midpoint. Overall, 3D Global Biotech has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does 3D Global Biotech's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3D Global Biotech ranks #450 out of 1319 companies for 3-Year ROIIC %. This puts 3D Global Biotech in the upper half of its industry. Historically, 3D Global Biotech's own 3-Year ROIIC % has ranged from 22.75 to 134.47 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on 3D Global Biotech and its competitors. 3D Global Biotech's current 3-Year ROIIC % is 22.75, which is 53% below median its own 10-year median of 47.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3D Global Biotech stock overvalued right now?
Based on GuruFocus' analysis, 3D Global Biotech (ROCO:6808) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$187.50, compared to a current price of NT$38.15 — trading 79.7% below its estimated fair value. The current 3-Year ROIIC % is 22.75, which is 53% below median its 10-year median of 47.90. 3D Global Biotech's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For 3D Global Biotech (ROCO:6808), the current 3-Year ROIIC % is 22.75 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3D Global Biotech (ROCO:6808) Overvalued in 2026?
Based on GuruFocus' analysis, 3D Global Biotech stock appears to be undervalued.
The current stock price of NT$38.15 is trading 79.7% below its estimated GF Value™ of NT$187.50.
GuruFocus considers 3D Global Biotech to be Significantly Undervalued.
Key valuation signals for ROCO:6808:
3-Year ROIIC %: 22.75 (53% below median its 10-year median of 47.90)
GF Value™: NT$187.50 vs. price of NT$38.15 (79.7% below fair value)
No single metric tells the full story. See the ROCO:6808 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3D Global Biotech Inc is engaged in the research and development of high-end medical equipment and biological 3D printing technology and the sale of medical Materials and other related products.
69GF Score
Get the complete analysis for ROCO:6808
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6808 has been successfully added to your 
